• Median Technologies’ annual report for the year ended Dec. 31, 2025 highlighted modest revenue growth driven entirely by its iCRO imaging-services business, supported by a record order backlog of EUR 76.6 million.
• Eyonis LCS reached a key inflection point with completion of pivotal studies, FDA 510(k) and CE-mark submissions filed in mid-2025, a first non-exclusive distribution agreement signed in December, then FDA clearance secured in early 2026.
• U.S. commercialization began on Feb. 18, 2026 under a phased rollout, with the first customer sites targeted to go live in Q3 2026.
• Two refinancing transactions in July and August 2025 reshaped liquidity, extending the cash runway into Q4 2026, with potential upside tied to warrant exercises.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Median Technologies SA published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.